Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY)

Research output: Contribution to journalArticle

Abstract

The Nepi ANtidiabetes StudY (NANSY) is a 5-year randomized, double-blind, placebo-controlled trial in Swedish primary care, examining whether the development of type 2 diabetes (T2D) and retinopathy (separately reported) would be delayed in 40- to 70-year-old subjects with impaired fasting glucose (IFG) who, in addition to lifestyle changes, were treated with either placebo or low-dosage sulphonylurea (SU) (1-mg glimepiride; Amaryl (R)). Of 274 subjects (163 men, 111 women), 138 were allocated to placebo (46.0% men, 56.8% women) and 136 to glimepiride (54.0% men, 43.2% women). The primary endpoint was conversion to diabetes. Average follow-up time was 3.71 years; 96 subjects converted to diabetes, 55 allocated to placebo and 41 to glimepiride (absolute difference 9.8%; p = 0.072). In conclusion, the study failed to support the notion that low-dose SU added to lifestyle changes in IFG subjects would help to delay the conversion to diabetes.

Details

Authors
  • U. Lindblad
  • Gunnar Lindberg
  • Nils-Ove Månsson
  • Jonas Ranstam
  • Maria Tyrberg
  • S. Jansson
  • K. Lindwall
  • Mona Svärdh
  • L. Kindmalm
  • Arne Melander
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Endocrinology and Diabetes

Keywords

  • IFG, prevention, primary care, randomized trial, sulphonylurea, type 2, diabetes
Original languageEnglish
Pages (from-to)185-188
JournalDiabetes, Obesity and Metabolism
Volume13
Issue number2
Publication statusPublished - 2011
Publication categoryResearch
Peer-reviewedYes